A Phase I Study of NX211 [OSI 211] Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors

Trial Profile

A Phase I Study of NX211 [OSI 211] Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs OSI 211 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top